ClinicalTrials.Veeva

Menu

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

X

Xi'an Jiaotong University

Status and phase

Unknown
Phase 3

Conditions

HER2+ Breast Cancer

Treatments

Drug: T-DM1
Drug: Capecitabine
Drug: Nab paclitaxel
Drug: Trastuzumab
Drug: AI
Drug: Everolimus
Drug: Pyrotinib
Drug: Pertuzumab
Drug: CDK4/6 inhibitor
Drug: Anti-PD-1 monoclonal antibody

Study type

Interventional

Funder types

Other

Identifiers

NCT05429684
XJTU1AF-CRF-2020-006

Details and patient eligibility

About

This is an open, prospective and interventional clinical study. Patients with advanced Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer resistant to trastuzumab will be enrolled in the study. Histological specimens obtained from different metastatic foci of patients, are used to conduct genome-wide sequencing together with Circulating tumor DNA (ctDNA) of blood samples. Meanwhile, investigator will construct PDO model based on biopsy tissue. Patients as well as their paired Patient-derived organoids (PDO) models are divided into six groups according to genomic signatures. Each group of patients will receive the best targeted treatment scheme from the current clinical perspective, while the matched PDO model will accept a variety of potential effective schemes intervention. The future treatment plan of patients will be timely adjusted based on the tumor inhibition rate of PDO models. This study is the first time to explore the best individualized application sequence of targeted therapy for refractory HER2 positive breast cancer by combining genome sequencing with drug sensitivity test of PDO model. The results are expected to improve the prognosis of patients with advanced HER2 positive breast cancer.

Full description

In previous studies, investigator found that dynamic genomics detection of metastatic foci can fully reveal the mechanism of trastuzumab resistance. Different anti-HER2 treatment strategies for different mechanisms can improve the efficacy of HER2 positive advanced breast cancer, and the PDO drug sensitivity test model of breast cancer can be prior to patients' response to the exact efficacy of specific regimens.This study aimed to explore the optimal individualized drug combination and order for patients with advanced HER2 positive breast cancer resistant to trastuzumab based on a variety of existing diagnosis and treatment methods. This is an open, prospective and interventional clinical study. Patients with advanced HER2 positive breast cancer resistant to trastuzumab will be enrolled in the study. Histological specimens obtained from different metastatic foci of patients, are used to conduct genome-wide sequencing together with ctDNA of blood samples. Meanwhile, investigator will construct PDO model based on biopsy tissue. Patients as well as their paired PDO models are divided into six groups according to genomic signatures. Each group of patients will receive the best targeted treatment scheme from the current clinical perspective, while the matched PDO model will accept a variety of potential effective schemes intervention. The future treatment plan of patients will be timely adjusted based on the tumor inhibition rate of PDO models. This study is the first time to explore the best individualized application sequence of targeted therapy for refractory HER2 positive breast cancer by combining genome sequencing with drug sensitivity test of PDO model. The results are expected to improve the prognosis of patients with advanced HER2 positive breast cancer.

Enrollment

120 estimated patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18-70 years old;
  2. Women;
  3. ECOG score 0-2;
  4. Locally advanced or metastatic breast cancer confirmed by histopathology;
  5. Positive HER2 expression in cancer tissues (IHC 3 +, or IHC 2 + but FISH amplification);
  6. Resistant to trastuzumab (including disease progression during or after withdrawal of trastuzumab);
  7. There were enough specimens for immunohistochemistry, gene detection and establishment of PDO model;
  8. Hematology and liver and kidney function were normal within 2 weeks before treatment;
  9. Imaging examination showed measurable lesions (according to RECIST v1.1);
  10. Women of childbearing age agree to contraception or take contraceptive measures;
  11. Be able to understand the research program and participate voluntarily.

Exclusion criteria

  1. Symptomatic, untreated or progressive central nervous system metastases;
  2. Severe heart disease (poor cardiac function);
  3. Within 5 years, there was a history of other malignant tumors other than breast cancer;
  4. In this study, chemotherapy, radiotherapy, immunotherapy or surgery were performed within 3 weeks before the first treatment;
  5. Patients who are pregnant or lactating, or plan to become pregnant during enrollment.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

120 participants in 6 patient groups

A. HER2 low expression
Experimental group
Description:
Phenotype was signatured by HER2 low expression.
Treatment:
Drug: Pertuzumab
Drug: Nab paclitaxel
Drug: Trastuzumab
B. HER2 amplified
Experimental group
Description:
Signatured by wild type HER2 amplified.
Treatment:
Drug: Pertuzumab
Drug: Nab paclitaxel
Drug: Trastuzumab
C. HER2 mutation
Experimental group
Description:
Signatured by HER2 mutation.
Treatment:
Drug: Capecitabine
Drug: Pyrotinib
D. HER2 downstream mutation
Experimental group
Description:
Signatured by HER2 downstream mutation of PI3KCA, TP53 or PTEN.
Treatment:
Drug: Everolimus
Drug: Nab paclitaxel
Drug: Trastuzumab
Drug: T-DM1
E. Hormone receptor pathway activation
Experimental group
Description:
Signatured by both ER and PR strongly expressed,or CCND1 amplified.
Treatment:
Drug: CDK4/6 inhibitor
Drug: AI
Drug: Trastuzumab
F. Immune activation
Experimental group
Description:
Signatured by high TMB or PD-L1 positively expressed.
Treatment:
Drug: Anti-PD-1 monoclonal antibody
Drug: Trastuzumab

Trial contacts and locations

2

Loading...

Central trial contact

Jin Yang, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems